Herm Rosenman Sells 48,419 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) Director Herm Rosenman sold 48,419 shares of the firm’s stock in a transaction on Friday, December 12th. The shares were sold at an average price of $227.42, for a total transaction of $11,011,448.98. Following the sale, the director owned 20,342 shares in the company, valued at approximately $4,626,177.64. This trade represents a 70.42% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Natera Stock Performance

Shares of NASDAQ:NTRA opened at $225.49 on Thursday. Natera, Inc. has a 52-week low of $125.38 and a 52-week high of $246.90. The firm has a fifty day moving average of $210.11 and a 200 day moving average of $178.07. The firm has a market capitalization of $31.19 billion, a PE ratio of -98.47 and a beta of 1.63.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The firm had revenue of $592.18 million for the quarter, compared to analysts’ expectations of $514.55 million. During the same quarter in the previous year, the business earned ($0.26) EPS. The company’s revenue for the quarter was up 34.7% on a year-over-year basis. On average, sell-side analysts forecast that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have commented on NTRA shares. Barclays increased their price target on shares of Natera from $230.00 to $270.00 and gave the company an “overweight” rating in a research report on Monday. BTIG Research increased their target price on shares of Natera from $230.00 to $260.00 and gave the company a “buy” rating in a report on Friday, December 5th. Royal Bank Of Canada set a $268.00 target price on shares of Natera and gave the stock an “outperform” rating in a research report on Tuesday, September 2nd. Wells Fargo & Company upped their price target on shares of Natera from $190.00 to $205.00 and gave the company an “equal weight” rating in a research report on Monday. Finally, BNP Paribas raised Natera to a “hold” rating and set a $172.00 price objective on the stock in a research note on Monday, October 27th. Fifteen equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $229.12.

Institutional Trading of Natera

Several large investors have recently modified their holdings of NTRA. Townsquare Capital LLC raised its position in Natera by 65.8% during the 1st quarter. Townsquare Capital LLC now owns 2,600 shares of the medical research company’s stock valued at $368,000 after purchasing an additional 1,032 shares during the last quarter. Corient IA LLC purchased a new position in shares of Natera during the first quarter valued at approximately $283,000. Summit Securities Group LLC bought a new position in shares of Natera during the first quarter valued at approximately $39,000. Northern Trust Corp raised its holdings in shares of Natera by 1.7% during the first quarter. Northern Trust Corp now owns 712,730 shares of the medical research company’s stock valued at $100,787,000 after acquiring an additional 11,949 shares in the last quarter. Finally, Korea Investment CORP purchased a new stake in Natera in the first quarter worth $5,657,000. 99.90% of the stock is owned by institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.